Advanced BioDesign is a pre-clinical stage biotechnology company focused on addressing chemotherapy-resistant cancers, particularly those with elevated levels of ALDH1 enzymes. Founded in 2010, the company has established the critical role of ALDH1 in cancer cell metabolism and immunomodulation. Advanced BioDesign has developed a pipeline of ALDH1 inhibitors, with its lead candidate, ABD-3001, currently in clinical trials targeting acute myeloid leukemia (AML). Initial results indicate a favorable safety profile, and the company is also advancing a second lead compound, ABD-0171, aimed at solid tumors, which shows enhanced efficacy when used in combination with anti-PD1 therapies.

In addition to its drug development efforts, Advanced BioDesign has created ALDESCREEN®, a predictive and prognostic test designed to identify and stratify patients based on their ALDH1 levels. This innovative approach aims to overcome tumor chemoresistance and reactivate endogenous cell death mechanisms in cancer cells. The company's strategy is to transform oncology treatment by providing targeted therapies that can improve outcomes for patients facing difficult-to-treat cancers, including non-small cell lung cancer and melanoma, among others.

France

Founded in 2010, Advanced BioDesign is a clinical stage company developing a highly promising therapy for cancer with high unmet medical needs. Advanced Biodesign has developed a therapeutic approach based on a selective inhibition of ALDH enzymes.
Advanced Biodesign project consist in the development of small-molecule that will selectively inhibit specific ALDH enzyme. By targeting this family of enzyme, will block specifically the intracellular mechanism of detoxification that cancerous cells have developed in order to escape form the programmed cell death called apoptosis.

Advanced Biodesign

Company Details